SurModics (SRDX) Names Andy LaFrence as CFO
SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced the appointment of Andy LaFrence as the company’s Vice President of Finance and Chief Financial Officer, effective February 12, 2013. He will lead all of the financial activities of SurModics, including controlling, financial planning and analysis, treasury, tax, audit and investor relations. LaFrence will succeed Timothy Arens, who currently serves as interim Chief Financial Officer. Arens will remain with the company and will transition into the role of Vice President of Corporate Development and Strategy. In his new role, Mr. Arens will lead the company’s efforts in developing strategies and assessing growth opportunities for its Medical Device and In Vitro Diagnostics businesses.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SurModics to Webcast Third Quarter 2015 Earnings Conference Call on August 5
- SurModics to Present at the InvestMNt Conference on August 5
- Twitter (TWTR) CEO Search Still Anyone's Game Following Square's Confidential IPO Filing